Search Results 171-180 of 17292 for egfr

  1. MSC For Occlusive Disease Of The Kidney - Mayo Clinic

    Advanced CKD: Stage 5 (two kidney eGFR < 15 ml/min/1.73 m2) contralateral renal artery occlusion/stenosis above 75% or ESRD requiring dialysis; Clinically ...

  2. A Study Of Depressive Symptoms In ADPKD - Mayo Clinic

    include confirmed clinical diagnosis of ADPKD using Pei-Ravine criteria, age 18-70, Pre-End Stage Kidney Disease, with Stage 1-5 CKD (eGFR >10 ml/min/1.73m2 ...

  3. Small Cell Lung Cancer Clinical Trials

    ... (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions. A Global Study To Assess The Effects Of Durvalumab + Domvanalimab Following Concurrent ...

  4. Perfusion MRI for Therapy Response Assessment in Brain Cancer - Mayo Clinic

    Evidence of normal kidney function (eGFR of > 60 ml/min/1.72 m^2) as assessed by laboratory testing (or eGFR immediately prior to MRI scan if laboratory ...

  5. Polycystic Kidney Disease Clinical Trials - Mayo Clinic Research

    ... (eGFR > 60 mL/min/m2, BP<130 0="" mmhg),="" and="" these="" correlate="" with ... (eGFR) decline in patients at risk of rapidly progressive Autosomal ...

  6. The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 (Cohort 1 and 3), or eGFR ≥ 30 to < 60 mL/min/1.73 m2 (Cohort 2 and 4), with eGFR calculated ...

  7. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). - Mayo Clinic

    ... (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions. Participation eligibility. Participant eligibility includes age, gender, type and stage of ...

  8. A Study To Assess Adverse Events And Effectiveness Of IntraVenous Infusions Of ABBV-CLS-628 In Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Mayo Clinic

    * Estimated glomerular filtration rate (eGFR) \>= 30 mL/min/1.73 m\^2 and \< 90 mL/min/1.73 m\^2, using the Chronic Kidney Disease Epidemiology ...

  9. Belimumab With Rituximab for Primary Membranous Nephropathy (REBOOT) - Mayo Clinic

    eGFR ≥ 30 mL/min/1.73m2 while on maximally tolerated RAS blockade 5. Proteinuria: 1. ≥ 4 and \< 8 g/day that has persisted for at least the previous 3 ...

  10. Publications - Xia Zhou, M.B., Ph.D. - Mayo Clinic

    HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS One. 2012; 7 (11):e49418 Epub ...